6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

PERSEPHONE Steering Committee and Trial Investigators

Research output: Contribution to journalArticlepeer-review

89 Citations (Scopus)
116 Downloads (Pure)

Fingerprint

Dive into the research topics of '6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial'. Together they form a unique fingerprint.

Medicine & Life Sciences